Literature DB >> 17914718

N-in-1 dosing pharmacokinetics in drug discovery: experience, theoretical and practical considerations.

Kan He1, Mingxin Qian, Harvey Wong, Stephen A Bai, Bing He, Bernice Brogdon, James E Grace, Baomin Xin, Jingtao Wu, Shelly X Ren, Hang Zeng, Yuzhong Deng, Danielle M Graden, Timothy V Olah, Steve E Unger, Joseph M Luettgen, Robert M Knabb, Donald J Pinto, Patrick Y S Lam, James Duan, Ruth R Wexler, Carl P Decicco, David D Christ, Scott J Grossman.   

Abstract

N-in-1 (or cassette) dosing pharmacokinetics (PK) has been used in drug discovery for rapid assessment of PK properties of new chemical entities. However, because of potential for drug-drug interactions this procedure is still controversial. This study was to retrospectively evaluate the N-in-1 dosing approach in drug discovery with an emphasis on the potential for drug-drug interactions. The systemic clearance, volume of distribution, oral bioavailability, and renal excretion of the 31 lead compounds in rats, dogs or chimpanzees were significantly correlated between the N-in-1 dosing and discrete studies with r values of 0.69, 0.91, 0.53, and 0.83 (p < 0.005 for all), respectively. PK parameters for 11 quality control compounds which were involved in 194 N-in-1 studies for screening approximately 1000 compounds had coefficient of variations of less than 70%. The intrinsic microsomal clearances generated from the N-in-1 and discrete incubations were nearly identical (r = 0.97, p < 0.0001). The intrinsic clearances of quality control compound from the N-in-1 incubations were consistent with its discrete CL(int) estimate (cv: 5.4%). Therefore, N-in-1 dosing is a useful approach in drug discovery to quickly obtain initial PK estimates. Potential drug-drug interactions that result in confounding PK estimates do not occur as frequently as expected.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17914718     DOI: 10.1002/jps.21196

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  8 in total

1.  Predicting drug candidate victims of drug-drug interactions, using microdosing.

Authors:  Marie Croft; Brendan Keely; Ian Morris; Lan Tann; Graham Lappin
Journal:  Clin Pharmacokinet       Date:  2012-04-01       Impact factor: 6.447

2.  Combined use of in vitro phototoxic assessments and cassette dosing pharmacokinetic study for phototoxicity characterization of fluoroquinolones.

Authors:  Yoshiki Seto; Ryo Inoue; Masanori Ochi; Graham Gandy; Shizuo Yamada; Satomi Onoue
Journal:  AAPS J       Date:  2011-07-08       Impact factor: 4.009

3.  Integrated pharmacokinetic-driven approach to screen candidate anticancer drugs for brain tumor chemotherapy.

Authors:  Hua Lv; Xiaoping Zhang; Jyoti Sharma; M V Ramana Reddy; E Premkumar Reddy; James M Gallo
Journal:  AAPS J       Date:  2012-11-22       Impact factor: 4.009

4.  Screening candidate anticancer drugs for brain tumor chemotherapy: pharmacokinetic-driven approach for a series of (E)-N-(substituted aryl)-3-(substituted phenyl)propenamide analogues.

Authors:  Hua Lv; Fan Wang; M V Ramana Reddy; Qingyu Zhou; Xiaoping Zhang; E Premkumar Reddy; James M Gallo
Journal:  Invest New Drugs       Date:  2012-03-01       Impact factor: 3.850

Review 5.  Pharmacokinetic/ pharmacodynamic-driven drug development.

Authors:  James M Gallo
Journal:  Mt Sinai J Med       Date:  2010 Jul-Aug

6.  Simultaneous analysis of multiple monoclonal antibody biotherapeutics by LC-MS/MS method in rat plasma following cassette-dosing.

Authors:  Hongyan Li; Robert Ortiz; Linh T B Tran; Hossein Salimi-Moosavi; Jennifer Malella; Christopher A James; Jean W Lee
Journal:  AAPS J       Date:  2012-12-12       Impact factor: 4.009

7.  From basic science to life-saving therapy: the rationale, and drug discovery efforts that led to the direct factor Xa inhibitor eliquis.

Authors:  Robert M Knabb; Ruth R Wexler
Journal:  J Thromb Thrombolysis       Date:  2021-08-05       Impact factor: 2.300

8.  A Large Impact of Obesity on the Disposition of Ivermectin, Moxidectin and Eprinomectin in a Canine Model: Relevance for COVID-19 Patients.

Authors:  Alain Bousquet-Mélou; Anne Lespine; Jean-François Sutra; Isabelle Bargues; Pierre-Louis Toutain
Journal:  Front Pharmacol       Date:  2021-05-20       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.